Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

Dowsett, Mitch
Cuzick, Jack
Coombes, Charles
Snowdon, Claire
Gnant, Michael
Jakesz, Raimund
Kaufmann, Manfred
Boccardo, Francesco
Godwin, Jon
Davies, Christina
Peto, Richard
Ingle, Jim
Coates, Alan
Forbes, John
Bliss, Judith
Buyse, Marc
Baum, Michael
Buzdar, Aman
Colleoni, Marco

January 2010

Purpose: To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with t...

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

Corona S. P.
Roviello G.
Strina C.
Milani M.
Madaro S.
Zanoni D.
Allevi G.
Aguggini S.
Cappelletti M. R.
Francaviglia M.
Azzini C.
Cocconi A.
Sirico M.
Bortul M.
Zanconati F.
Giudici F.
Rosellini P.
Meani F.
Pagani O.
Generali D.

January 2019

Background: Endocrine treatment with Tamoxifen and aromatase inhibitors (AIs) is a staple in the man...

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

Ferretti G
Giannarelli D
Felici A
Papaldo P
Fabi A
Di Cosimo S
Ruggeri EM
Milella M
Ciccarese M
Cecere FL
Gelibter A
Nuzzo C
Cognetti F
Terzoli E
Carlini P.
Bria, Emilio

January 2006

The purpose of this study was to estimate in all randomised trials the relative risk of overall resp...

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Dowsett, M
Forbes, J. F
Bradley, R
Ingle, J
Aihara, T
Bliss, J
Boccardo, F
Coates, A
Coombes, R. C
Cuzick, J
Dubsky, P
Gnant, M
Kaufmann, M
Kilburn, L
Perrone, F
Rea, D
Thürlimann, B
van de Velde, C
Pan, H
Peto, R
Davies, C
Gray, R
DE LAURENTIIS, MICHELINO

January 2015

The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast ...

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

October 2015

SummaryBackgroundThe optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment ...

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomised trials

Bradbury, R
Braybrooke, J
Gray, R
Hills, R
Liu, Z
Pan, H
Peto, R
Dodwell, D
McGale, P

January 2022

Background: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamo...

Aromatase inhibitors versus tamoxifen in early breast cancer:patient-level meta-analysis of the randomised trials

October 2015

Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for ea...

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:Patient-level meta-analysis of randomised trials

August 2011

Background: As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormon...

Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients

Bria, Emilio
Ciccarese M
Giannarelli D
Cuppone F
Nisticò C
Nuzzo C
Natoli G
Fabi A
Terzoli E
Cognetti F
Carlini P.

January 2006

BACKGROUND: The magnitude of the survival benefit of aromatase inhibitors (AIs) after 2-3 years of t...

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

DOWSETT M
CUZICK J
INGLE J
COATES A
FORBES J
BLISS J
BUYSE M
BAUM M
BUZDAR A
COLLEONI M
COOMBES C
SNOWDON C
GNANT M
JAKESZ R
KAUFMANN M
BOCCARDO, FRANCESCO
GODWIN J
DAVIES C
PETO R.

January 2010

J Clin Oncol. 2010 Jan 20;28(3):509-18. Meta-analysis of breast cancer outcomes in adjuvant trials...

Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

Robertson, John F.R.
Paridaens, Robert J.
Lichfield, Jasmine
Bradbury, Ian
Campbell, Christine

March 2021

Background Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast ca...

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo : Meta-analyses on efficacy and adverse events based on randomized clinical trials

Rydén, Lisa
Arnlind, Marianne Heibert
Vitols, Sigurd
Höistad, Malin
Ahlgren, Johan

January 2016

Tamoxifen (TAM) and aromatase inhibitors (AI) are adjuvant therapy options for postmenopausal women ...

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.

Boccardo, Francesco
Rubagotti, Alessandra
Aldrighetti, D
Buzzi, F
Cruciani, G
Farris, A
Mustacchi, G
Porpiglia, M
Schieppati, G
Sismondi, P.

January 2007

Cancer. 2007 Mar 15;109(6):1060-7. Switching to an aromatase inhibitor provides mortality benefit in...

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

Dowsett, Mitch
Cuzick, Jack
Coombes, Charles
Snowdon, Claire
Gnant, Michael
Jakesz, Raimund
Kaufmann, Manfred
Boccardo, Francesco
Godwin, Jon
Davies, Christina
Peto, Richard
Ingle, Jim
Coates, Alan
Forbes, John
Bliss, Judith
Buyse, Marc
Baum, Michael
Buzdar, Aman
Colleoni, Marco

January 2010

Purpose: To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with t...

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

Corona S. P.
Roviello G.
Strina C.
Milani M.
Madaro S.
Zanoni D.
Allevi G.
Aguggini S.
Cappelletti M. R.
Francaviglia M.
Azzini C.
Cocconi A.
Sirico M.
Bortul M.
Zanconati F.
Giudici F.
Rosellini P.
Meani F.
Pagani O.
Generali D.

January 2019

Background: Endocrine treatment with Tamoxifen and aromatase inhibitors (AIs) is a staple in the man...

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

Ferretti G
Giannarelli D
Felici A
Papaldo P
Fabi A
Di Cosimo S
Ruggeri EM
Milella M
Ciccarese M
Cecere FL
Gelibter A
Nuzzo C
Cognetti F
Terzoli E
Carlini P.
Bria, Emilio

January 2006

The purpose of this study was to estimate in all randomised trials the relative risk of overall resp...

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Dowsett, M
Forbes, J. F
Bradley, R
Ingle, J
Aihara, T
Bliss, J
Boccardo, F
Coates, A
Coombes, R. C
Cuzick, J
Dubsky, P
Gnant, M
Kaufmann, M
Kilburn, L
Perrone, F
Rea, D
Thürlimann, B
van de Velde, C
Pan, H
Peto, R
Davies, C
Gray, R
DE LAURENTIIS, MICHELINO

January 2015

The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast ...

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

October 2015

SummaryBackgroundThe optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment ...

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomised trials

Bradbury, R
Braybrooke, J
Gray, R
Hills, R
Liu, Z
Pan, H
Peto, R
Dodwell, D
McGale, P

January 2022

Background: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamo...

Aromatase inhibitors versus tamoxifen in early breast cancer:patient-level meta-analysis of the randomised trials

October 2015

Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for ea...

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:Patient-level meta-analysis of randomised trials

August 2011

Background: As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormon...

Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients

Bria, Emilio
Ciccarese M
Giannarelli D
Cuppone F
Nisticò C
Nuzzo C
Natoli G
Fabi A
Terzoli E
Cognetti F
Carlini P.

January 2006

BACKGROUND: The magnitude of the survival benefit of aromatase inhibitors (AIs) after 2-3 years of t...

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

DOWSETT M
CUZICK J
INGLE J
COATES A
FORBES J
BLISS J
BUYSE M
BAUM M
BUZDAR A
COLLEONI M
COOMBES C
SNOWDON C
GNANT M
JAKESZ R
KAUFMANN M
BOCCARDO, FRANCESCO
GODWIN J
DAVIES C
PETO R.

January 2010

J Clin Oncol. 2010 Jan 20;28(3):509-18. Meta-analysis of breast cancer outcomes in adjuvant trials...

Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

Robertson, John F.R.
Paridaens, Robert J.
Lichfield, Jasmine
Bradbury, Ian
Campbell, Christine

March 2021

Background Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast ca...

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo : Meta-analyses on efficacy and adverse events based on randomized clinical trials

Rydén, Lisa
Arnlind, Marianne Heibert
Vitols, Sigurd
Höistad, Malin
Ahlgren, Johan

January 2016

Tamoxifen (TAM) and aromatase inhibitors (AI) are adjuvant therapy options for postmenopausal women ...

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.

Boccardo, Francesco
Rubagotti, Alessandra
Aldrighetti, D
Buzzi, F
Cruciani, G
Farris, A
Mustacchi, G
Porpiglia, M
Schieppati, G
Sismondi, P.

January 2007

Cancer. 2007 Mar 15;109(6):1060-7. Switching to an aromatase inhibitor provides mortality benefit in...

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

Dowsett, Mitch
Cuzick, Jack
Coombes, Charles
Snowdon, Claire
Gnant, Michael
Jakesz, Raimund
Kaufmann, Manfred
Boccardo, Francesco
Godwin, Jon
Davies, Christina
Peto, Richard
Ingle, Jim
Coates, Alan
Forbes, John
Bliss, Judith
Buyse, Marc
Baum, Michael
Buzdar, Aman
Colleoni, Marco

January 2010

Purpose: To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with t...

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

Corona S. P.
Roviello G.
Strina C.
Milani M.
Madaro S.
Zanoni D.
Allevi G.
Aguggini S.
Cappelletti M. R.
Francaviglia M.
Azzini C.
Cocconi A.
Sirico M.
Bortul M.
Zanconati F.
Giudici F.
Rosellini P.
Meani F.
Pagani O.
Generali D.

January 2019

Background: Endocrine treatment with Tamoxifen and aromatase inhibitors (AIs) is a staple in the man...

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

Ferretti G
Giannarelli D
Felici A
Papaldo P
Fabi A
Di Cosimo S
Ruggeri EM
Milella M
Ciccarese M
Cecere FL
Gelibter A
Nuzzo C
Cognetti F
Terzoli E
Carlini P.
Bria, Emilio

January 2006

The purpose of this study was to estimate in all randomised trials the relative risk of overall resp...

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Abstract

Extracted data

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Abstract

Extracted data

Topics

Related items

Topics

Related items